Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.
Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. PWS is due to lack of several genes on one of an individual’s two chromosome 15’s. In the majority of cases, there is a deletion. In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15’s from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 6, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.
Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prader-Willi Syndrome (PWS) - Overview
Prader-Willi Syndrome (PWS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Prader-Willi Syndrome (PWS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
Aardvark Therapeutics Inc
Altamira Therapeutics Ltd
Benuvia Therapeutics Inc
Beryl Therapeutics Inc
Biomind Labs Inc
Bioprojet SCR
Carmot Therapeutics Inc
ConSynance Therapeutics Inc
Ferring International Center SA
GLWL Research Inc
Helsinn Group
Inversago Pharma Inc
Lipidio Pharmaceuticals Inc
Lumos Pharma Inc
Neuracle Science Co Ltd
Neuren Pharmaceuticals Ltd
Notitia Biotechnologies Co
OptiNose Inc
OT4B
Saniona AB
Soleno Therapeutics Inc
Taysha Gene Therapies Inc
Tonix Pharmaceuticals Holding Corp
Prader-Willi Syndrome (PWS) - Drug Profiles
(metoprolol + tesofensine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
betahistine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Prader Willi Syndrome - Drug Profile
Product Description
Mechanism Of Action
Bittera - Drug Profile
Product Description
Mechanism Of Action
BMND-04 - Drug Profile
Product Description
Mechanism Of Action
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
carbetocin LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
CSTI-500 - Drug Profile
Product Description
Mechanism Of Action
diazoxide choline CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
GDD-3898 - Drug Profile
Product Description
Mechanism Of Action
GLWL-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-04 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HU-671 - Drug Profile
Product Description
Mechanism Of Action
ibutamoren mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
INV-202 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MRI-1867 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NM-136 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NNZ-2591 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NS-200 - Drug Profile
Product Description
Mechanism Of Action
oxytocin - Drug Profile
Product Description
Mechanism Of Action
oxytocin - Drug Profile
Product Description
Mechanism Of Action
History of Events
oxytocin - Drug Profile
Product Description
Mechanism Of Action
History of Events
oxytocin - Drug Profile
Product Description
Mechanism Of Action
History of Events
pitolisant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit SMCHD1 for Prader Willi Syndrome - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Target Incretin for Prader-Willi syndrome - Drug Profile
Product Description
Mechanism Of Action
History of Events
TSHA-116 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Prader-Willi Syndrome (PWS) - Dormant Projects
Prader-Willi Syndrome (PWS) - Discontinued Products
Prader-Willi Syndrome (PWS) - Product Development Milestones
Featured News & Press Releases
Mar 09, 2022: Running for research - Prader-Willi Syndrome to fund multi-center study of DCCR in early phase Prader-Willi syndrome
Mar 03, 2022: Tonix Pharmaceuticals announces FDA Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi Syndrome
Feb 28, 2022: Tonix Pharmaceuticals announces research agreement with the French National Institute of Health and Medical Research (Inserm) to study the mechanism of oxytocin-mediated improvement of eating behaviors in Prader-Willi Mice
Feb 03, 2022: Aardvark starts enrolment in three Phase II trials of TAS2R agonist
Jan 24, 2022: Soleno Therapeutics provides regulatory update on DCCR for the treatment of Prader-Willi syndrome
Dec 28, 2021: Saniona initiates phase 2b clinical trial of tesomet for Prader-Willi syndrome
Oct 18, 2021: Saniona completes submission of manufacturing data for Tesomet capsules to U.S. FDA
Oct 11, 2021: US patent to 2034 granted for Neuren’s NNZ-2591 in autism
Sep 17, 2021: adMare Portfolio Company, Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 Blocker
Sep 08, 2021: Soleno Therapeutics announces positive data showing continued significant improvements in symptoms of PWS following one year treatment with DCCR
Sep 07, 2021: Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 blocker
Sep 03, 2021: FDA grants Orphan Drug Designation for NNZ-2591 to treat Prader-Willi syndrome
Jul 26, 2021: Saniona receives U.S. FDA orphan drug designation for Tesomet in hypothalamic obesity
Jul 22, 2021: Radius Health announces plans for global Prader-Willi syndrome pivotal study
Jul 06, 2021: Soleno Therapeutics provides regulatory update on DCCR for the treatment of Prader-Willi syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Prader-Willi Syndrome (PWS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Prader-Willi Syndrome (PWS) - Pipeline by 9 Meters Biopharma Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Aardvark Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Altamira Therapeutics Ltd, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Benuvia Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Beryl Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Biomind Labs Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Bioprojet SCR, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Carmot Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by ConSynance Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, 2022
Prader-Willi Syndrome (PWS) - Pipeline by GLWL Research Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Helsinn Group, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Inversago Pharma Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Lipidio Pharmaceuticals Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Lumos Pharma Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Neuracle Science Co Ltd, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Neuren Pharmaceuticals Ltd, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Notitia Biotechnologies Co, 2022
Prader-Willi Syndrome (PWS) - Pipeline by OptiNose Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by OT4B, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Taysha Gene Therapies Inc, 2022
Prader-Willi Syndrome (PWS) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Prader-Willi Syndrome (PWS) - Dormant Projects, 2022
Prader-Willi Syndrome (PWS) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Prader-Willi Syndrome (PWS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
